Davol INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$27Mgeneral payments (2019-2025)
$903Kresearch payments (2019-2025)
26,490clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $3.1M
2020 $6.9M
2021 $2.0M
2022 $2.6M
2023 $3.2M
2024 $3.4M
2025 $5.7M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Plastic Surgery $9.6M
Surgery $9.2M
Thoracic Surgery (Cardiothoracic Vascular Surgery) $1.5M
Adult Reconstructive Orthopaedic Surgery $907K
Orthopaedic Surgery $820K
Colon & Rectal Surgery $562K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Robert Rehnke St Petersburg, FL Plastic Surgery $6,053,539.88
John Fischer Philadelphia, PA Plastic Surgery $2,398,761.42
Javad Parvizi Philadelphia, PA Adult Reconstructive Orthopaedic Surgery $853,142.38
John Roth Lexington, KY Surgery $711,814.97
Stephen Kovach Philadelphia, PA Plastic Surgery $570,909.79
Steven Demeester Portland, OR Thoracic Surgery (Cardiothoracic Vascular Surgery) $532,159.21
Ara Klijian Murrieta, CA Thoracic Surgery (Cardiothoracic Vascular Surgery) $408,295.59
Rasa Zarnegar New York, NY Surgery $397,058.13
Bruce Van Natta Indianapolis, IN $387,108.95
Kristopher Lybarger Kansas City, MO Gynecologic Oncology $342,921.46

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.